Cover Image
Market Research Report

Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019

Published by Global Markets Direct Product code 361645
Published Content info 48 Pages
Delivery time: 1-2 business days
Price
Back to Top
Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019
Published: December 27, 2019 Content info: 48 Pages
Description

Summary

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.

The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC2087TDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
  • CJ HealthCare Corp
  • KinDex Pharmaceuticals Inc
  • MorphoSys AG
  • Novopyxis Inc
  • Vicore Pharma AB
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
  • (amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KDT-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MOR-107 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NP-6A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VP-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VP-02 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
  • Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
  • Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
  • Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01
  • Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out
  • Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF
  • Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis
  • Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor
  • Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
  • Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
  • Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
  • Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and Indicate Effects on lipid Metabolism
  • May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
  • Mar 08, 2017: C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis
  • Mar 03, 2017: New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21
  • Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by CJ HealthCare Corp, H2 2019
  • Pipeline by KinDex Pharmaceuticals Inc, H2 2019
  • Pipeline by MorphoSys AG, H2 2019
  • Pipeline by Novopyxis Inc, H2 2019
  • Pipeline by Vicore Pharma AB, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top